Key Takeaways
- Revenue surges on inventory liquidation and demand recovery: Revenue grew 148.8% YoY and 50.5% sequentially, with 25-30% of the quarter's revenue coming from the clearance of older inventory that customers had previously deferred.
- Margins are temporarily depressed, normalization promised: Consolidated EBITDA margins of ~19.5% for Q2 were weighed down by dispatches from older, lower-margin inventory; management expects a recovery to a ~25% (±1%) steady-state from Q3 onward.
- The balance sheet is healing fast: Working capital days halved from 409 to 247, net debt is down, and operating cash flow turned significantly positive at Rs. 300+ crore after two years of cash absorption.
- A large, completed CapEx cycle is now set to contribute: The Rs. 678 crore investment from September 2022 is fully operational; revenues from these new plants will start flowing from here, addressing the prior disconnect between gross block growth and stagnant EBITDA.
- What to watch next quarter: Whether the promised margin normalization to 25% materializes, the pace of further working capital reduction toward the 200-day target, and the receipt of the Rs. 350 crore trapped cash from overseas subsidiaries.
Revenue Performance & Drivers
- Agrochemical cycle turns positive: The core agrochemical segment saw a volume-led recovery after a prolonged downturn, marking a clear inflection point for the business.
- Pharma and polymers drive diversification: The pharma segment grew 201% YoY to 23% of H1 revenue, while performance materials (polymers) grew 306% YoY to 16% of H1 revenue, supported by new product launches and the ramp-up of recently commercialized molecules.
- Inventory liquidation provided a one-off boost: Management had been requesting customers to take delivery of older, underwritten inventory; the resulting clearance contributed 25-30% of Q2 revenue, a tailwind that will not repeat at this scale.
- US market insulated from tariff risk: The majority of Anupam's products fall under the exempt category for recently imposed US tariffs, protecting export competitiveness and margins in a key growth market where performance was "phenomenal."
Anand Desai: "I am pleased to highlight that within just six months of this financial year, we have already surpassed the total revenue of FY25, demonstrating the resilience of our business model, strong customer relationships, and operational excellence."
Margin Walk & Normalization Path
- The Q2 margin drag is mechanical, not structural: Consolidated EBITDA margin of ~19.5% reflects the sale of older inventory carrying a comparatively lower margin profile. Approximately Rs. 150 crore (30% of revenue) came from these lower-margin areas.
- The steady-state target is 25%: Management guided for margins to stabilize around 25% with a ±1% variation band, starting from Q3, as new contracts and pricing structures take effect and the inventory mix normalizes.
- H1 FY26 margin sits at ~25.5%: The first-half average already approximates the target, reinforcing that Q2 was an isolated low point driven by mix.
Balance Sheet & Cash Flow Repair
- Working capital cycle is compressing rapidly: Working capital days fell from 409 in FY25 to 247 in H1 FY26, driven by inventory liquidation and a tightening of receivables. Management targets a further reduction to 200 days in the near term.
- Cash flow has flipped from absorption to generation: After two years of consuming cash, the business generated Rs. 300+ crore from operations, reducing net debt and reliance on external financing for current operations.
- A Rs. 350 crore intercompany receivable is a timing issue: The standalone balance sheet shows elevated debtors because wholly-owned US and Europe subsidiaries have collected from end-customers but not yet remitted to the parent. Management expects this cash to be received in the current quarter or month.
- Inventory investment is now deliberate, not distressed: While older inventory has been liquidated, the company is consciously building working capital in the pharma and performance chemicals segments to support growth, creating a two-way dynamic on the balance sheet.
Vishal Thakkar: "So now business has started giving back cash than what it was absorbing for the last two years."
The CapEx Overhang: Assets Now Ready to Yield
- The Rs. 1,000 crore gross block puzzle is resolved: The increase in gross block from Rs. 1,400 crore (FY22) to Rs. 3,400 crore (FY25) reflected assets under construction that were not yet revenue-generating. The September 2022 CapEx of Rs. 678 crore is now fully completed and put to use.
- Revenue contribution begins now: Management confirmed that revenues from these new plants will start contributing from this point onward, addressing the key investor question of why past CapEx did not translate into incremental EBITDA during the agrochemical downturn.
Vishal Thakkar: "The Rs. 1,000 crores that is invested is now asset put to use because it was a combination of the three plants which we have invested, which are going to now start yielding the revenue because those were under construction." [10-11]
Customer Behavior & Working Capital History
- Inventory build-up was customer-driven: During the agrochem downturn, customers underwrote inventory but requested supply deferral as they liquidated their own channel inventory, leaving finished goods on Anupam's balance sheet.
- Debtor days stretched, now snapping back: To support multi-decadal customer relationships during the market headwind, Anupam accommodated requests for longer payment cycles. Debtor days, which had stretched from 97 (FY22) to 266 (FY25), have now compressed back to 107 days.
- The 700-day inventory question reflects this history: When challenged on why inventory holding periods far exceed competitors' sub-150-day levels, management attributed the gap to the unique circumstance of customer-deferred supply rather than a permanent operating model difference.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 50%+ growth for FY26, driven by agrochemical recovery, pharma and polymers | FY26 |
| EBITDA margin | Stabilize at ~25% (±1%) as new contracts and pricing take effect | From Q3 FY26 onward |
| Working capital days | Reduce to 200 days in the near term | Near term, with more meaningful results over 18 months |
| Operating cash flow | Continue delivering Rs. 300+ crore from operations | Ongoing |
| Intercompany cash receipt | Receive Rs. 350 crore from US/Europe subsidiaries | Current quarter/month |
| New plant revenue contribution | Revenue from the completed Rs. 678 crore CapEx to begin flowing | From here onward |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue from operations | ₹731.40 cr, up 148.8% YoY and 50.5% QoQ |
| H1 FY26 revenue from operations | ₹1,217.22 cr, up 122.1% YoY; surpassed full FY25 revenue in six months |
| EBITDA (incl. other income) | ₹143.58 cr, up 74.4% YoY; margin of 19.5% |
| H1 FY26 EBITDA margin | ~25.5%, slightly subdued due to dispatches from older inventory |
| Profit after tax | ₹57.15 cr, up 86.6% YoY; PAT margin of 7.8% |
| H1 FY26 PAT | ₹105.61 cr, up 146.6% YoY; PAT margin of 8.6% |
| FY26 revenue growth guidance | 50%+, driven by agro recovery and growth in polymer and pharma |
| EBITDA margin guidance | ~25%, with a variation of plus or minus 1 ppt |
| Order book | ~₹14,646 cr, spread over 5–7 years |
| Exports share of revenue | 58% of total revenue |
| Top 10 customer concentration | 81% of revenue from operations |
| Life Science Related Specialty Chemicals share | 84% of H1 FY26 revenue |
| Pharma segment YoY growth | 201% in H1 FY26; 23% of total H1 revenue |
| Performance Materials YoY growth | 306% in H1 FY26; 16% of total H1 revenue |
| Revenue from older inventory liquidation | 25%–30% of Q2 revenue |
| Net debt | ₹730 cr at consolidated level, after repaying ₹175 cr of term debt from warrant proceeds |
| Working capital days | 247 days in H1 FY26, down from 409 days in FY25; near-term target of 200 days |
| Operating cash flow (consolidated) | Over ₹350 cr in H1 FY26 |
| Tanfac Industries H1 FY26 revenue | ₹344.7 cr, up 66.6% YoY |